A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity

Next-generation COVID-19 vaccines are being developed to expand the breadth of coverage against existing and future variants and to extend the duration of protection. Prime-2-CoV_Beta is an orf virus (ORFV) based multi-antigen COVID-19 vaccine that co-expresses Spike (S) and Nucleocapsid (N) antigen...

Full description

Saved in:
Bibliographic Details
Main Authors: Ute Klinkhardt, Mirjam Schunk, John Ervin, Christoph Schindler, Danny Sugimoto, Bruce Rankin, Ralf Amann, Martina Monti, Anna Kutschenko, Carsten Schumacher, Kristina Huber, Andreas Zeder, Nelli Heikkila, Arnaud M. Didierlaurent, Sylvia E. Schwarz, Madiha Derouazi
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
SARS-CoV-2 variants
COVID-19
booster vaccine
ORF virus-vector
first-in-human trial
immunogenicity
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2410574
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2410574

Similar Items